Prevalence of and risk factors for low bone mineral density in Spanish treated HIV-infected patients.

Miguel Cervero-JimenezRafael TorresJose Luís AgudVictoria AlcázarJuan José JusdadoConcepción García-LacalleSantiago Moreno

Published in: PloS one (2018)

We have confirmed a high prevalence of reduced BMD, which is favoured by ritonavir-boosted PI and TDF. Bone safety should continue to be evaluated in clinical trials and cohort studies in order to demonstrate that the new drugs offer additional advantages regarding the impact on BMD.

Keyphrases

bone mineral density
hiv infected patients
antiretroviral therapy
clinical trial
postmenopausal women
body composition
risk factors
phase ii
randomized controlled trial
study protocol
open label
drug induced
phase iii
soft tissue